The convergence of AI, non-invasive diagnostics, and preventive care creates the most consequential MedTech investment window of the decade.
iGlutek's addressable market is defined conservatively — focusing first on the highest-intent cohort (Type 1 & 2 diabetes with CGM dependency) before expanding into the broader preventive health wearable market.
iGlutek competes in a quadrant no device currently occupies: multi-biomarker, non-invasive, AI-predictive, and zero consumable cost.
| Company / Product | iGlutek | Abbott FreeStyle | Dexcom G7 | Apple Watch Ultra | Samsung Galaxy |
|---|---|---|---|---|---|
| Needles / Skin Penetration | ✓ None | ✗ Filament | ✗ Filament | ✓ None | ✓ None |
| Glucose Measurement | ✓ NIR | ✓ Electrochemical | ✓ Electrochemical | ✗ Not available | ✗ Not available |
| Number of Biomarkers | 11+ | 1 | 1 | 4 | 3 |
| Predictive AI (48h) | ✓ Yes | Trend only | Trend only | ✗ No | ✗ No |
| Recurring Cost (monthly) | ✓ €0 | €80–100 | €90–120 | €0 | €0 |
| Regulatory Status | R&D Phase | CE + FDA cleared | CE + FDA cleared | FDA cleared (limited) | SaMD registered |
| Federated AI Learning | ✓ Yes | ✗ No | ✗ No | Partial | ✗ No |
537M diabetics globally, projected 783M by 2045. Every year without iGlutek costs patients €2,400–€6,000.
Edge AI chips and transformer architectures now enable on-device inference at sub-100ms — impossible 3 years ago.
FDA SaMD guidance and EU MDR create clear pathways for AI-powered non-invasive diagnostics for the first time.
EU and US healthcare systems under severe cost pressure — preventive monitoring over acute intervention is now policy priority.
Over 700M wearable devices sold in 2024. Consumers expect their watch to tell them more than their doctor visits do.
GDPR and HIPAA enforcement creates competitive moat for privacy-by-design architectures — iGlutek's core differentiator.